Income Statement APT Medical Inc.
Equities
688617
CNE100004C45
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
346.20 CNY | -0.99% | -0.52% | +29.21% |
Aug. 23 | APT Medical's H1 Profit Rises 33%, Operating Income Climbs 27%; Shares Drop 3% | MT |
Aug. 22 | APT Medical Inc. Reports Earnings Results for the Half Year Ended June 30, 2024 | CI |
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 404M | 478M | 823M | 1.2B | 1.64B | ||
Other Revenues, Total | - | 1.5M | 5.82M | 11.55M | 8.49M | ||
Total Revenues | 404M | 479M | 829M | 1.22B | 1.65B | ||
Cost of Goods Sold, Total | 118M | 142M | 259M | 354M | 486M | ||
Gross Profit | 286M | 337M | 570M | 862M | 1.16B | ||
Selling General & Admin Expenses, Total | 122M | 153M | 250M | 308M | 387M | ||
Provision for Bad Debts | 1.09M | 283K | -511K | 790K | -178K | ||
R&D Expenses | 70.42M | 71.9M | 135M | 175M | 238M | ||
Other Operating Expenses | 4.26M | 6.14M | 8.14M | 13.75M | 14.52M | ||
Other Operating Expenses, Total | 198M | 232M | 393M | 497M | 639M | ||
Operating Income | 88.03M | 106M | 177M | 365M | 525M | ||
Interest Expense, Total | -258K | -1.41M | -1.63M | -1.45M | -3.69M | ||
Interest And Investment Income | 685K | 1.21M | 13.26M | 23.94M | 27.74M | ||
Net Interest Expenses | 427K | -207K | 11.64M | 22.49M | 24.05M | ||
Currency Exchange Gains (Loss) | - | -431K | -1M | 1.17M | 2.66M | ||
Other Non Operating Income (Expenses) | -603K | -334K | -499K | -490K | -35.61K | ||
EBT, Excl. Unusual Items | 87.85M | 105M | 187M | 388M | 552M | ||
Impairment of Goodwill | - | - | - | - | -3.84M | ||
Gain (Loss) On Sale Of Investments | -1.01M | -67.73K | 21.72M | 342K | - | ||
Gain (Loss) On Sale Of Assets | -909 | -231K | -51.8K | 56.21K | 11.97M | ||
Asset Writedown | -76.92K | - | -3.5M | -10.68M | -123K | ||
Other Unusual Items | 4.59M | 16.83M | 16.58M | 17.25M | 36.83M | ||
EBT, Incl. Unusual Items | 91.36M | 121M | 222M | 395M | 596M | ||
Income Tax Expense | 13.28M | 17.02M | 26.7M | 54.98M | 74.24M | ||
Earnings From Continuing Operations | 78.08M | 104M | 195M | 340M | 522M | ||
Net Income to Company | 78.08M | 104M | 195M | 340M | 522M | ||
Minority Interest | 4.5M | 6.58M | 13.07M | 17.86M | 11.79M | ||
Net Income - (IS) | 82.57M | 111M | 208M | 358M | 534M | ||
Net Income to Common Incl Extra Items | 82.57M | 111M | 208M | 358M | 534M | ||
Net Income to Common Excl. Extra Items | 82.57M | 111M | 208M | 358M | 534M | ||
Per Share Items | |||||||
Net EPS - Basic | 1.14 | 1.53 | 2.2 | 3.71 | 5.54 | ||
Basic EPS - Continuing Operations | 1.14 | 1.53 | 2.2 | 3.71 | 5.54 | ||
Basic Weighted Average Shares Outstanding | 72.5M | 72.36M | 94.51M | 96.49M | 96.29M | ||
Net EPS - Diluted | 1.14 | 1.53 | 2.19 | 3.66 | 5.46 | ||
Diluted EPS - Continuing Operations | 1.14 | 1.53 | 2.19 | 3.66 | 5.46 | ||
Diluted Weighted Average Shares Outstanding | 72.5M | 72.36M | 95.11M | 97.95M | 97.75M | ||
Normalized Basic EPS | 0.82 | 1 | 1.37 | 2.7 | 3.7 | ||
Normalized Diluted EPS | 0.82 | 1 | 1.37 | 2.66 | 3.65 | ||
Dividend Per Share | - | 0.34 | 0.69 | 1.14 | 1.38 | ||
Payout Ratio | 7.23 | 1.28 | 15.97 | 19.28 | 21.02 | ||
Supplemental Items | |||||||
EBITDA | 103M | 125M | 204M | 405M | 580M | ||
EBITA | 89.76M | 108M | 177M | 367M | 528M | ||
EBIT | 88.03M | 106M | 177M | 365M | 525M | ||
EBITDAR | 105M | 128M | 205M | 406M | 581M | ||
Total Revenues (As Reported) | 404M | 479M | 829M | 1.22B | 1.65B | ||
Effective Tax Rate - (Ratio) | 14.54 | 14.04 | 12.05 | 13.91 | 12.45 | ||
Total Current Taxes | 13.85M | 17.33M | 34.9M | 55.62M | 79.14M | ||
Total Deferred Taxes | -565K | -307K | -8.2M | -642K | -4.9M | ||
Normalized Net Income | 59.41M | 72.01M | 130M | 260M | 357M | ||
Interest Capitalized | - | 131K | 82.6K | - | - | ||
Interest on Long-Term Debt | - | - | 522K | 436K | 693K | ||
Supplemental Operating Expense Items | |||||||
Marketing Expenses | - | 21.01M | 33M | 41.59M | 46.16M | ||
Selling and Marketing Expenses | 88.97M | 114M | 195M | 241M | 305M | ||
General and Administrative Expenses | 33.03M | 39.56M | 55.12M | 66.55M | 82.26M | ||
Research And Development Expense From Footnotes | 70.42M | 71.9M | 135M | 175M | 238M | ||
Net Rental Expense, Total | 1.96M | 2.3M | 741K | 726K | 933K | ||
Imputed Operating Lease Interest Expense | 54.32K | 321K | 237K | 170K | 387K | ||
Imputed Operating Lease Depreciation | 1.9M | 1.98M | 505K | 556K | 547K | ||
Stock-Based Comp., R&D Exp. (Total) | - | - | 9.17M | 11.43M | 8.96M | ||
Stock-Based Comp., S&M Exp. (Total) | - | - | 4.06M | 4.09M | 3.46M | ||
Stock-Based Comp., G&A Exp. (Total) | - | - | 3.96M | 4.63M | 5.07M | ||
Stock-Based Comp., Other (Total) | 2.57M | - | 971K | 1.6M | 829K | ||
Total Stock-Based Compensation | 2.57M | - | 18.17M | 21.75M | 18.32M |